XNAS · SXTP
+5.65% · +$0.0500 · Vol 24.2K
After hours · updated 16:00:00 ET
60 Degrees Pharmaceuticals, Inc. Common Stock

60 Degrees Pharmaceuticals, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$1.01
Card
Relationship Map

Follow $SXTP

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $SXTP by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock
Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

54/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is SXTP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading SXTP catalysts
About 60 Degrees Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
3
Country
US

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.9800
Day high
$1.02
Day low
$0.9400
Previous close
$0.9560
52W high
$1.02
-0.97% from high
52W low
$0.9400
88% of range
Market cap
$3.4M
EPS
$-4.4000
Shares out
3.5M
Volume
24.2K
VWAP
$0.9822
Price history computed in-house
SMA 50 Not reported · Not reported
SMA 200 Not reported · Not reported
52W position 88%

SXTP overview

Veridion Score
54
Registered · 2026-09-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around SXTP.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading SXTP Form 4 filings
Public disclosures

Congress activity in SXTP

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for SXTP in the cached public ledger.

Federal contracts

SXTP contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for SXTP in this window.
Lobbying spend

SXTP lobbying filings, year to date.

Registered lobbying filings matched to 60 Degrees Pharmaceuticals, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for SXTP in this window.
Loading news for SXTP
Analyst ratings
Sovereign unlock shows live analyst consensus for SXTP.
Options
Sovereign unlock shows live options positioning for SXTP.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.